However, for advanced non-small cell lung cancers (NSCLCs) harboring driver mutations such as EGFR or ALK mutations, immunotherapy exhibited impaired response compared to corresponding targeted therapies4–6. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.